Definium Therapeutics, Inc.
DFTX
$17.64
-$0.45-2.49%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.96% | 17.41% | -3.00% | -16.04% | -7.48% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 60.04% | 61.43% | 44.02% | 19.60% | 10.71% |
| Operating Income | -60.04% | -61.43% | -44.02% | -19.60% | -10.71% |
| Income Before Tax | -69.12% | -71.88% | -12.23% | 38.06% | -13.52% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -69.12% | -71.88% | -12.23% | 38.06% | -13.52% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -69.12% | -71.88% | -12.23% | 38.06% | -13.52% |
| EBIT | -60.04% | -61.43% | -44.02% | -19.60% | -10.71% |
| EBITDA | -60.71% | -113.14% | -182.44% | -425.28% | -- |
| EPS Basic | -13.85% | 0.72% | 39.67% | 67.80% | 26.26% |
| Normalized Basic EPS | -11.65% | 2.47% | 40.60% | 66.60% | 24.81% |
| EPS Diluted | -2.23% | 9.66% | 37.01% | 56.07% | 15.14% |
| Normalized Diluted EPS | -11.94% | 2.27% | 40.96% | 67.16% | 25.23% |
| Average Basic Shares Outstanding | 26.88% | 43.00% | 66.35% | 91.61% | 79.82% |
| Average Diluted Shares Outstanding | 25.05% | 40.48% | 65.72% | 96.26% | 83.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |